Thrombosis is a well recognised feature of systemic lupus erythematosus (SLE). Both clinically detected arterial or venous thrombosis and low grade coagulation activation manifest by features such as glomerular thrombi and fibrin deposition in lupus nephritis have been described. 1 2 One factor already identified in association with thrombosis is the presence of the lupus anticoagulant, an antiphospholipid antibody which interferes with in vitro coagulation tests.' 3The mechanism whereby this antibody predisposes to thrombosis is unknown, though it may block conversion of arachidonic acid to prostacyclin (PGI2), a potent inhibitor of platelet 4 aggregation.
Under normal physiological conditions activation of coagulation automatically stimulates the release of plasminogen activator (PA) from the vascular endothelium.5 Plasminogen activator is the major regulator of fibrinolysis and prevents unwanted fibrin deposition. The potential of the fibrinolytic system can be assessed by inducing venous occlusion in an arm and assaying plasminogen activator activity, which normally increases six-to eightfold over resting levels. 'Poor responders' to venous occlusion may be identified, who frequently show a tendency towards fibrin deposition.6 Such a defect has been implicated in recurrent venous thrombosis, postphlebitic syndrome, coronary artery disease, and diabetic microangiopathy,7-9 and in some reports is associated with release of excessive amounts of PA inhibitor, which is also secreted by the endothelium.10 This present study was designed to assess the fibrinolytic system in patients with SLE. Eleven patients were not receiving any therapy at the time of the study, 41 were taking corticosteroids, and 20 were taking cytotoxic drugs. Nineteen patients were receiving non-steroidal antiinflammatory drugs, usually naproxen, and two were taking low dose aspirin (300 mg twice weekly). A variety of other drugs were used by some patients, most frequently diuretics (13 patients) and 13 blockers (eight patients).
In addition to assays of fibrinolytic proteins, haematological, biochemical, and serological tests were performed. Healthy subjects drawn from laboratory and secretarial staff were examined to obtain control data.
Plasminogen activator activity was assayed in venous blood samples taken after 20 minutes of supine rest and after 10 minutes of venous occlusion at 80 mmHg.12 Blood was anticoagulated with one tenth volume 0*1 M trisodium citrate, then cooled on ice and centrifuged at 2000 g (4°C) for 10 minutes. Euglobulin fractions were obtained by addition of 9-5 ml of cold acetic acid (0-014%) to 0 5 ml plasma. After 15 minutes on ice the samples were spun at 2000 g for 10 minutes, the supernatants discarded, and the precipitates redissolved in 0-5 ml of 50 mM NaCl/27-6 mM sodium barbitone/HCl buffer, pH 7*4. Plasminogen activator activity was assayed by applying 50 i.l euglobulin--fractions (in duplicate) to fibrin plates within 45 minutes of drawing the blood. Fibrin plates (9 cm diameter) were prepared using bovine fibrinogen (10 ml, 2 
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ronectin and von Willebrand factor antigen were both greatly raised in the patients (p<0001), but the mean levels of plasminogen activator activity both before and after venous occlusion were not significantly different in patients and controls. Fig. 1 shows the frequency distribution of the response to venous occlusion. Poor response was here defined as failure to demonstrate PA activity >0 3 CTA U/ml in response to venous occlusion.9 Twenty five of 72 (35%) patients were poor responders, compared with two of 22 (9%) controls (X2=4-2, p<0-05).
When the results for plasma factors in SLE responders were compared with those for poor responders (Table 3 ) no significant differences were found between mean values, though the poor responders showed a tendency towards greater 
